IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4047
EU - Europa 3501
AS - Asia 2008
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
SA - Sud America 4
Totale 9584
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4031
CN - Cina 1973
IE - Irlanda 1654
UA - Ucraina 462
FI - Finlandia 374
DE - Germania 289
SE - Svezia 225
IT - Italia 169
GB - Regno Unito 100
AT - Austria 97
BE - Belgio 51
FR - Francia 51
CA - Canada 16
IR - Iran 11
IN - India 9
MU - Mauritius 9
AU - Australia 6
RU - Federazione Russa 6
EU - Europa 5
GR - Grecia 5
HK - Hong Kong 5
NL - Olanda 5
CL - Cile 4
RO - Romania 4
TR - Turchia 3
DK - Danimarca 2
ES - Italia 2
IL - Israele 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ID - Indonesia 1
IQ - Iraq 1
JP - Giappone 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
ZA - Sudafrica 1
Totale 9584
Salva come PNG Salva come JPEG
Città #
Dublin 1654
Chandler 1325
Jacksonville 659
Nanjing 569
Princeton 259
Lawrence 251
Nanchang 249
Medford 238
Wilmington 209
Beijing 205
Shenyang 179
Hebei 162
Changsha 156
Ann Arbor 143
Jiaxing 132
Tianjin 104
Hangzhou 90
Boardman 78
Vienna 74
Helsinki 66
Woodbridge 64
Brussels 51
Norwalk 51
Pavia 51
Milan 37
Fairfield 30
Ningbo 22
Verona 22
Des Moines 18
Zhengzhou 18
Houston 17
Kunming 16
Toronto 13
Induno Olona 12
Redwood City 11
Auburn Hills 10
Taizhou 10
Tamm 9
Jinan 8
Fuzhou 6
Orange 6
San Francisco 6
Shanghai 5
Berlin 4
Borås 4
Falls Church 4
Guangzhou 4
Haikou 4
Lanzhou 4
San Genesio Ed Uniti 4
Sydney 4
Andover 3
Catania 3
Changchun 3
Dearborn 3
Detroit 3
Seattle 3
Zanjan 3
Ashburn 2
Athens 2
Cambridge 2
Chicago 2
Chignolo d'Isola 2
Falkenstein 2
Gunzenhausen 2
Kemerovo 2
Las Vegas 2
Latisana 2
London 2
Los Angeles 2
Markham 2
Nagold 2
Novokuznetsk 2
Rockville 2
Sacramento 2
Seelze 2
Torino 2
Vinovo 2
Alexandria 1
Ardabil 1
Bari 1
Bloomfield 1
Cairo 1
Canberra 1
Charlotte 1
Clearwater 1
Copenhagen 1
Dallas 1
Doncaster 1
Freetown 1
Gijón 1
Groningen 1
Hanover 1
Hefei 1
Hunedoara 1
Indianapolis 1
Jinhua 1
Kish 1
Leawood 1
Leidschendam 1
Totale 7410
Salva come PNG Salva come JPEG
Nome #
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 81
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 80
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 79
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 77
Bone marrow amyloidosis. 77
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 74
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 74
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 74
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 73
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 71
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 70
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 69
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 69
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 68
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 68
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 68
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 65
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 65
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 64
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 62
Light chain amyloidosis 2012: a new era. 61
Comment on: parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's Syndrome. 60
Holter monitoring in AL amyloidosis: prognostic implications. 60
Biochemical markers in early diagnosis and management of systemic amyloidoses 60
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 59
Amyloid typing: immunoelectron microscopy 59
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 58
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 58
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 58
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 58
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 57
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 57
Clinical aspects of systemic amyloid diseases. 57
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 57
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 57
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 57
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 57
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 56
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 56
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 56
Clotting alterations in primary systemic amyloidosis. 55
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 55
Treating advanced cardiac damage in light chain amyloidosis: still an unmet need 55
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 55
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 54
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. 54
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 54
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective 54
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 54
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 54
The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation 53
End-stage renal failure due to amyloidosis and recurrent fever on dialysis--is there a link? 53
Bortezomib in a Phase 1 Trial for Patients with Relapsed AL Amyloidosis: Cardiac Responses and Overall Effects 53
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes 53
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 53
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 53
Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis 52
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 52
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. 52
First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome 52
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 51
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 51
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 51
AMICA: an electronic patient record specifically designed for an amyloidosis network. 51
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis 51
Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis 50
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 50
Light chain amyloidosis: the heart of the problem 50
Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis 50
Therapy and management of systemic AL (primary) amyloidosis 49
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 49
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 49
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 49
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 49
Protein Aggregation 49
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 48
Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis 48
Enlightening light chain deposition disease 48
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 47
Bortezomib in the treatment of AL amyloidosis: targeted therapy? 47
Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma 47
Current treatment of AL amyloidosis 47
Systemic amyloidoses: what an Internist should know 47
Ovarian hyperstimulation syndrome in systemic amyloidosis 47
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis 47
A patient with AL amyloidosis with negative free light chain results 47
AMICA: an electronic patient record specifically designed for an amyloidosis network 47
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 46
Hepatic amyloidosis with light chain deposition disease. A rare association. 46
Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center 46
Immune mechanism of AL amyloidosis. 46
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 46
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 46
Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis 45
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis 45
La rilevanza diagnostica e prognostica del peptide natriuretico di tipo B (BNP) e del suo frammento N terminale (NT-proBNP) nei pazienti con amiloidosi AL e insufficienza renale 45
Renal involvement in systemic amyloidosis 45
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 45
A workflow management system for the biological samples exchange within the amyloidosis network 45
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 45
Totale 5563
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23950
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23950
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182 0000 00 00 0002
2018/2019493 321913 111 1334 1038727
2019/20202413 695984191 994 33100 92249578
2020/20211075 1248531101 7131 16192 8514712630
2021/20221102 21102611 3219 1191 6142155623
2022/20234135 43627847286 351350 74227 1932411121
Totale 10004